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ABSTRACT 
Two peptides derived from the C1B domain of protein kinase C (PKC)  were shown to 
associate with classical PKC isozymes and modulate their activities. These C1B peptides 
are designated C1B1 (amino acid residues 101-112) and C1B5 (residues 141-151). Since 
PKC enzyme activity is shown to be involved in colon cancer development, the effect of 
C1B peptides on the growth of various human colon cancer cell lines was examined in 
vitro and in vivo. Sub-micromolar to micromolar levels of both C1B peptides induced 
approximately 60-70% growth attenuation in multiple colon cancer cell lines in a soft 
agar tumor colony assay; however, C1B5 peptide was not cytotoxic to normal colon 
epithelial cells in two dimensional culture. The effect of C1B5 peptide on colony growth 
of COLO205 cells was reversed by treatment with the PKC inhibitor, Ro-32-0432. 
C1B peptide treatment attenuated COLO205 cells via two mechanisms: 1) cell cycle 
arrest and 2) stimulation of apoptosis. This is evident in G2 arrest and increases in levels 
of cleaved caspase 3 and p53 phosphorylated at serine 20.  Intratumoral injection of C1B5 
peptide (20 mg/kg/day, every three days) markedly attenuated the growth of 
subcutaneous xenografts of COLO205 cells in SCID mice by 76% compared to the 
control. Taken together, these results strongly suggest that C1B peptides have negligible 
effects on normal tissues but are potentially effective chemotherapeutic agents for colon 
cancer. 
 
Key Words: C1B domein peptides, Protein kinase Cγ (PKCγ), PKCII, C1B domain, 
colon cancer, xenograft, COLO205 colon carcinoma cells, cancer therapy.  
 
Abbreviations: DAG, diacylglycerol; DMEM, Dulbecco's Modified Eagle Medium; 
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FBS, Fetal bovine serum; PKC, Protein kinase C; RIE-1, rat intestinal epithelial-1; TCF, 
a transcription factor in Wnt signaling  
 
Introduction 
  In the USA, colon cancer is the second leading cause of cancer mortality.  Of the 
estimated 102,900 new cases in 2010, 51,370 resulted in death.1 Recent research indicates 
that the causes of colon cancers are related to non-inherited factors or environmental 
factors, which can cause somatic mutations of specific genes such as RB1, p16, ras, or 
p53.2 However, few targeted molecular therapies have progressed to clinical trials for the 
treatment of colon cancer. Therefore, it is clear that novel treatment strategies are 
urgently needed. 
   Protein kinase C (PKC) is a family of serine/threonine kinases that plays a central role 
in cell proliferation, differentiation, and apoptosis.3-5 The PKC isozymes are divided into 
three subfamilies based on their structure and mode of action. The classic (or 
conventional) PKC subfamily includes α, βI, βII, and γ isozymes, which are activated by 
diacylglycerol (DAG) and phosphatidylserine in a calcium-dependent manner. The 
atypical PKCs (λ, ζ and ι) are activated by phosphatidylserine in a calcium-independent 
manner. The novel PKCs (δ, ε, θ and η) are activated by DAG and phosphatidylserine in a 
calcium-independent manner. Although PKCs have overlapping substrate specificities in 
vitro, they exhibit distinct patterns of tissue expression and intracellular localization. The 
structure of all PKCs is composed of an N-terminal regulatory region, which consists of a 
pseudosubstrate region and C1 and C2 domains (atypical PKCs lack the C2 domain), and 
a C-terminal catalytic region, which contains the C3 and C4 domains. The C1 domains in 
the conventional and novel PKCs are highly homologous and consist of a tandem repeat 
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of two cysteine-rich zinc-finger motifs (C1A, C1B). These subdomains are the binding 
sites for the PKC activator DAG and for its functional analogs, phorbol esters, which 
compete with DAG for the same binding site and can activate PKC.3, 6 
   Recently, Nguyen et al.7 demonstrated that synthetic C1B subdomain peptides C1B1 
and C1B5 bind to 14-3-3ε docking protein competitively, dissociate the docking protein 
and activate PKCγ. Since the C1B1 or C1B5 subdomain peptides potentially act as 
decoys and interact with multiple C1B domain-associated signaling proteins, they may 
affect cell proliferation, differentiation, and apoptosis through PKC regulation. However, 
the relationship between C1B subdomain peptide-dependent PKC regulation and 
carcinogenesis has not been rigorously studied.  
   The roles of the PKC family in cell growth, apoptosis, invasion, and differentiation are 
known to occur by transduction of mitogenic signaling pathways.8  The initial study 
showing that PKC is activated by phorbol esters suggested that PKCs are tumor 
promoters.3, 9 However, it has been reported that different PKC isozymes have distinct 
and sometimes opposing effects.10 For example, PKCδ expression has decreased 
azoxymethane-induced rat colon tumors and sporadic human colon tumors.11, 12 In 
addition, PKCδ activation in the human colon cancer cell line Caco-2 has been reported to 
induce differentiation and attenuate both anchorage-dependent and independent cell 
growth.13 In contrast to the observations suggesting that PKCδ attenuates tumor growth, 
studies suggest that PKCβII promotes tumor growth.  For example, PKCβII is 
progressively induced in azoxymethane-induced colon carcinogenesis in mice.14 Recent 
studies using transgenic mice over-expressing PKCβΙI show hyperproliferation of the 
colonic epithelium and high susceptibility to carcinogen-induced colon cancer.15, 16 These 
studies also revealed that PKCβII-dependent hyperproliferation of the colonic epithelium 
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is associated with reduction of glycogen synthase kinase 3β activity and increased 
β-catenin expression. These results indicate that PKCβII induces colonic epithelial 
hyperproliferation through activation of a PKCβII/β-catenin/T-cell factor (TCF; Wnt 
signaling) axis.15 In addition, inhibition of PKCβII-mediated hyperproliferation in the 
colonic epithelium by N-3 fatty acids has been shown to be associated with attenuated 
tumor growth.16 Therefore, PKCβII is suggested to be pro-oncogenic in colon 
tumorigenesis.   
   Due to the complexity of the relationship between PKC regulation and carcinogenesis, 
the present study was undertaken to determine whether synthetic C1B peptides regulate 
growth of human colon carcinoma cells. Here, we report that synthetic C1B peptide 
significantly attenuates the growth of human colon carcinoma cells in vitro and in vivo. 
Interestingly, C1B5 peptide was found to be associated with phosphorylation of PKCα/β 
II, which led to the induction of apoptosis of colon carcinoma cells. Expression of PKCγ 
in human colon carcinoma cell lines was negligible; hence C1B5 peptide-induced growth 
regulation of colon carcinoma cells seems independent from PKCγ activation. 
 
Results 
C1B peptides inhibit anchorage independent growth of colon cancer cell lines. 
Colony formation by COLO205 cells in soft agar was significantly inhibited by 
sub-micromolar to micromolar concentrations of C1B1 or C1B5 peptides (Fig. 1A-B).  
However, colony growth attenuation by C1B5 treatment was stronger than C1B1 
treatment at 0.1µM. Since nonspecific scrambled peptide did not affect colony formation 
(Fig.1A), C1B domain peptide-dependent attenuation of colony formation is suggested to 
be sequence-specific. We also tested the effect of C1B5 peptide on colony growth 
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attenuation in different colon carcinoma cell lines. As shown in Fig. 1D, C1B5 peptide at 
1μM significantly attenuated the colony formation of two other human colon carcinoma 
cell lines, SW620 and Caco-2. In contrast, micromolar concentrations of C1B5 peptide 
did not show significant effects on cell viability of either COLO205 or normal intestinal 
epithelial cells in standard two-dimensional (2D) cell culture (Fig. 2). 
  The C1B5 peptide-dependent inhibitory action was blocked by PKC inhibitor. 
As shown in Fig. 1, C1B5 treatment significantly attenuated the colony growth of 
COLO205 cells. Treatment with the Ca2+ dependent PKC isozyme inhibitor 
Ro-32-0432 alone did not show any effects on colony growth of COLO205 cells (Fig. 3).  
Interestingly, treatment with 1 µM Ro-32-0432 counteracted the inhibition of colony 
growth of COLO205 cells by C1B5 peptide (Fig. 3). Although the concentration of 
Ro-32-0432 used was high enough to inhibit other PKC isozymes, such as PKCγ and 
possibly PKCε, 17 but not various other kinases, 18 this result suggests that classical PKC 
plays an important role in colony growth attenuation by C1B5 treatment.  
  The C1B5 peptide induces G2 arrest of the cell cycle and apoptosis via 
phosphorylation of p53 at serine 20, which is followed by reduction of 
phosphorylation of PKCII. In an effort to investigate the mechanism by which 
C1B5 peptide treatment attenuates cell proliferation and viability of colon carcinoma 
cells, COLO205 cells were treated with 1µM C1B5 peptide for 72 hours and the cell 
cycle and apoptosis were analyzed by flow cytometry and Western blot analysis. As 
shown in Fig. 4, treatment with C1B5 significantly increased the G2 population (Figs. 4A 
and B) and the percentage of early- and late-stage apoptotic cells (Fig. 4C and D) as 
compared to the PBS treated control cells. Western blot analysis also indicated that C1B5 
peptide treatment significantly increased the levels of cleaved caspase 3 and 
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phosphorylation of p53 at serine 20 without changing total p53 levels for at least 72 hours 
after the C1B5 treatment (Figs. 4E and F).  These results clearly indicate that C1B5 
peptide treatment causes G2 arrest and stimulates apoptosis of COLO205 cells. Although 
the enzymatic activity of PKCγ is suggested to be activated by C1B5 treatment,7 Western 
blot analysis in the present study revealed that PKCγ expression in COLO205 cells was 
barely detectible and was unaltered by C1B5 treatment (data not shown).  In contrast, it 
has been shown that PKCII plays an important role in tumorigenesis of colon cancer; the 
inhibition of PKCII can cause the induction of apoptosis in glioma and colon cancer 
cells.19 
  To better understand the mechanism by which C1B5 treatment induces apoptosis in 
COLO205 cells, the effect of C1B5 on the early phosphorylation of PKCII and p53 at 
serines 15 and 20, the levels of total PKCα, total PKCII, total p53, and cleaved 
caspase-3 were analyzed by Western blot.  As shown in Fig. 5, C1B5 treatment 
significantly reduced phosphorylation of PKCII in COLO205 without altering the 
expression of PKCII at 30-minutes after C1B5 treatment.  In contrast, the expression of 
PKCα was increased as compared to the control group (Fig. 5 B).  The level of cleaved 
caspase-3 was increased by C1B5 treatment at the 6-hour time point (Fig. 5 D-E). 
Phosphorylation of p53 at serine 20, but not at serine 15, was increased in a 
time-dependent manner with upregulation of total p53 levels (Fig. 5 F-G). These results 
indicate that C1B5 not only affects cell cycle by inducing G2 arrest but reduces 
phosphorylation of PKCII, which may lead to apoptosis via phosphorylation of p53 at 
serine 20.20 
  The intratumoral injection of C1B5 peptide significantly attenuated tumor growth. 
COLO205 cells were inoculated subcutaneously to both flanks of SCID mice (1x107cells 
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per site). After allowing the tumors to grow to an average size of 150 mm3, C1B5 or a 
scrambled peptide solution (10 mg/ml saline at 20 mg/kg body weight) was injected into 
the tumors every three days, while control mice received PBS injections. While both the 
PBS- and the scrambled peptide-injected tumors showed rapid growth during the 
treatment, the tumors treated with the C1B5 peptide showed markedly smaller increases 
in volume (PBS, 950.7mm3; scrambled peptide, 890.7mm3; C1B5, 290.2mm3 at day 36, 
Fig. 6A). The average weight of C1B5 peptide treated tumors was also significantly 
smaller than that of PBS- and scrambled peptide-injected tumors (Fig. 6B). Histological 
examination of tumor sections shows that the C1B5 treated tumors have fewer mitotic 
figures than the scrambled peptide and PBS control groups (Fig. 6C).  These results 
clearly indicate that C1B5 peptide treatment is capable of attenuating the tumor growth of 
the COLO 205 cell line in vivo by attenuating cell proliferation.  
C1B5 treatment markedly attenuated cell proliferation and increased apoptosis 
in tumor tissues. To evaluate the effect of C1B5 treatment on cell proliferation and 
apoptosis in tumor cells, numbers of Ki-67 and TUNEL positive cells in tumor tissues 
were determined. The number of Ki-67 positive cells was significantly higher in control 
tumors than in C1B5-treated tumors (Figs. 7 A, B, and E). The average numbers of Ki-67 
positive cells in 10 randomly selected fields in PBS-treated and C1B5-treated mouse 
tumors were 210 ± 9.9 and 130 ± 8.5/field, respectively (p < 0.05). TUNEL positive cell 
numbers increased in C1B5 treated tumors (Figs. 7 C, D, and F). The average numbers 
of TUNEL positive cells in 10 randomly selected fields in PBS-treated and C1B5-treated 
mouse tumors were 1.5 ± 0.2 and 4.1 ± 0.4 /field, respectively (p < 0.05). These results 
indicate that treatment with C1B5 attenuated cell proliferation and increased apoptosis 
significantly. 
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Discussion 
The PKC family has been known to play important roles in cell growth, apoptosis, 
invasion, and differentiation.8 Although PKC was considered to play a role in tumor 
promotion in the past,3, 9 the role of PKC in tumorigenesis is now recognized to be very 
complex, with different PKC isozymes having distinct and sometimes opposing effects. 10, 
21 Moreover, it has been shown that over-expression of the same PKC isozyme can lead to 
different biological effects depending on the character of the cell.21-23 For instance, HT29 
or SW480 human colon carcinoma cells over-expressing PKCβI display increased 
doubling time, decreased saturation density, and loss of anchorage-independent growth in 
soft agar following exposure to phorbol ester, as well as decreased tumorigenicity in nude 
mice.22, 23 In contrast, it was reported that PKCβI over-expression stimulates growth of rat 
embryonic fibroblasts.21 However, PKCα over-expression attenuates growth of the same 
rat embryonic fibroblasts.21 Moreover, the atypical PKC isozyme, PKCδ has been 
demonstrated to inhibit colon cancer cell growth and enhance differentiation and 
apoptosis. 13  Taken together, these studies suggest that while PKCs play important roles 
in tumorigenesis and tumor growth, their effects depend on the isozyme and cell type. 
Therefore, the aim of the present study was to evaluate the effect of C1B domain peptides, 
putative PKC activators, on the growth of human colon carcinoma cells in vivo and in 
vitro. The present study provides strong evidence that C1B domain peptides have 
therapeutic potential; they attenuate growth of colon carcinoma cells in vitro and in vivo.  
   In the current work, we examined the attenuation effect of C1B domain peptides, C1B1 
and C1B5, on multiple human colon carcinoma cell lines. As described in the results, 
both peptides significantly attenuated colony growth of multiple colon carcinoma cell 
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lines (Fig. 1). Comparing the growth inhibitory potential of the two peptides indicated 
that C1B5 peptide appears to be more potent than C1B1 peptide (Fig. 1). This 
peptide-dependent cell growth attenuation was clearly visible in 3D cell growth (colony 
growth in soft agar) but not in 2D cell culture (Fig. 2), which is a unique characteristic of 
this cell growth inhibition. Furthermore, C1B peptides did not affect growth of normal 
colon epithelial cells in 2D culture; although 3D and 2D cultures are not comparable, 
normal colon epithelial cells do not grow in 3D culture (Fig. 2). These results indicate 
that this C1B5 peptide may be an ideal cancer-targeted therapeutic peptide, since this 
peptide selectively attenuates growth of cancer cells.  
   In human colon cancer, PKCβII is suggested to be an important factor regulating cell 
growth15, 16. This is also supported by a study showing that a PKCβII inhibitor, 
enzastaurin, attenuates colon cancer cell growth by reducing expression of PKCβII.24 
Enzastaurin was also shown to attenuate the growth of colon cancer xenografts by 
inducing apoptosis.19 Our findings indicate a potential mechanism by which C1B peptide 
attenuates cancer cell growth. In the present study, the analysis of apoptosis with flow 
cytometric detection of annexin V positive cells indicated that C1B5 treatment increased 
cell surface annexin V, an early sign of apoptosis (Fig. 4). The induction of apoptosis was 
also verified by Western blot analysis. At 48 and 72 hours after C1B5 treatment, the levels 
of cleaved caspase-3 and phosphorylated p53 in COLO205 cells were significantly higher 
than those of the control (Figs. 4 D, E, and F).  In addition, the in vivo study showed that 
the number of TUNEL positive cells in the C1B5 treatment group was significantly 
higher than in the PBS-control group, supporting the in vitro results that C1B5 attenuated 
tumor growth of COLO205 through apoptosis induction. 
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   It is well known that the tumor suppressor protein p53 plays a central role in mediating 
stress and DNA damage-induced growth arrest and apoptosis.25 Phosphorylation of p53 
at serine 20 is shown to be associated with apoptosis induction as a result of DNA damage 
by radiation or chemotherapy and is therefore a potential target to attenuate tumor 
growth.20 The relationship between PKCII and p53 has yet to be fully understood.  
However,  inhibition of PKCII can induce apoptosis.19 Therefore, to better understand 
the relationship between C1B5 growth attenuation and apoptosis in COLO205 cells, the 
level of phosphorylation of p53 at serine 20 in COLO205 after C1B5 treatment was 
evaluated.  Our results indicate that the phosphorylation of p53 at serine 20 was increased 
time dependently (Fig. 5).  To the best of our knowledge, this is the first report that C1B5 
peptide attenuates tumor cell growth by inducing apoptosis via phosphorylation of p53 at 
serine 20, which is followed by decreased phosphorylation and subsequent inhibition of 
PKCII. Although this study cannot rule out a possibility that the C1B peptide also 
modifies PKCγ and regulates tumor cell growth, the recent discovery of the direct 
interaction between C1B peptide and PKCII 26 strongly supports our result that C1B5 
attenuated tumor growth through inhibition of phosphorylation of PKCII. Negligible 
expression of PKCγ in COLO205 may also support the above conclusion. 
   Flow cytometric analysis showed that G2 arrest was induced in COLO205 cells treated 
with 1 µM C1B5 peptide for 72 hours.  This suggests that growth attenuation by C1B5 
might also be associated with cell cycle arrest. Indeed, histological analysis of tumors 
showed significantly fewer mitotic cells in the C1B5 peptide-treated tumors than in 
PBS-treated tumors (Fig. 6D). The cell cycle is known to be an important factor in tumor 
growth regulation. In colon cancer, Pysz et al.27 revealed that transcriptional inhibition of 
cyclin D1 might play a role in tumor growth attenuation in association with up-regulation 
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of PKCα. PKCα, one of the classic PKC isozymes, is activated at the point of growth 
arrest in intestinal crypts in situ,28, 29 and PKCα signaling promotes cell cycle withdrawal 
in non-transformed intestinal epithelial cells.30 The tumor suppressor role of PKCα in the 
intestine is supported by studies using PKCα knockout mice, which showed increased 
proliferative activity within intestinal crypts and spontaneous intestinal adenoma 
formation.31 The findings in the present study that C1B5 peptide treatment increased the 
expression of PKCα in COLO205 cells and induced G2 arrest are in strong agreement 
with the aforementioned reports and suggest that C1B5 peptide also affects tumor growth 
through up-regulation of PKCα leading to G2 arrest. The G2 arrest observed in the in vitro 
study is supported by the in vivo immunohistochemical analysis, in which the number of 
Ki-67 positive cells in the C1B5 treatment group was significantly lower than in the PBS 
control group. 
   In summary, the present study demonstrates that C1B peptides significantly attenuate 
growth of multiple human colon carcinoma cells in three-dimensional cell culture without 
affecting the growth of normal intestinal epithelial cells.  The C1B peptide-dependent cell 
growth attenuation is potentially mediated through PKCII, and the mechanism is 
associated with phosphorylation of p53 at serine 20, and therefore with activation of 
intrinsic apoptosis. Treatment with C1B5 peptide significantly attenuated colon 
carcinoma tumor growth in a mouse xenograft study. These results clearly indicate that 
C1B peptides can be used as cancer-targeted therapeutics for human colon cancer.  
 
Materials and Methods 
Materials. Two C1B domain peptides, C1B1 (PKC residues 101–112; 
HKFRLHSYSSPT) and C1B5 (PKC residues 141–151, RCVRSVPSLCG) and a 
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nonspecific random sequence peptide (SFGKCHLYPKV) were synthesized by the 
Kansas State University Biotechnology Core Facility (Kansas State University, 
Manhattan, KS). Antibodies against PKC, PKCβII, phospho-PKC /II (Thr 638 in 
PKCα/Thr 641 in PKC βII), and cleaved caspase-3, p53, phospho-p53 at Ser 20 were 
purchased from Cell Signaling Technology (Danvers, MA); and antibodies against 
PKCII and GAPDH were from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal 
anti-Ki-67 antibody was from Abcam (Cambridge, MA). Horseradish 
peroxidase-conjugated anti-rabbit IgG antibody was from GE Healthcare (Uppsala, 
Sweden). Biotin-conjugated anti-rabbit IgG antibody was from Vector Laboratories 
(Burlingame, CA). Pierce SuperSignal Western Blotting substrate was from Pierce 
(Rockford, IL). RPMI 1640, low glucose Dulbecco's Modified Eagle Medium (DMEM) 
and Leibovitz's L-15 media were obtained from Mediatech, Inc. (Herndon, VA). Fetal 
bovine serum (FBS) was from Invitrogen (Carlsbad, CA).  
Cell lines and cell culture. Human colorectal adenocarcinoma cell lines (Caco-2, 
COLO 205, and SW620) and rat intestinal epithelial (RIE-1) were purchased from 
American Type Culture Collection (Manassas, VA). Caco-2 and COLO 205 cells were 
cultured with RPMI1640 medium supplemented with 10% FBS, 100 units/ml penicillin 
and 100 μg/ml streptomycin, and cultured in 5% CO2 humidified air at 37°C. SW620 
cells were cultured with Leibovitz's L-15 medium supplemented with 5% FBS, 100 
units/ml penicillin and 100 μg/ml streptomycin, and cultured in 5% CO2 humidified air at 
37°C. RIE-1 cells were maintained in DMEM supplemented with 10% FBS, 100 units/ml 
penicillin and 100 μg/ml streptomycin and cultured at 37°C under an atmosphere 
containing 5% CO2. 
  Effect of C1B5 on cell growth in vitro. RIE-1 or COLO205 cells were seeded at 3 x 
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105 cells per well in 24-well plates in 10% FBS-containing DMEM or RPMI1640, 
respectively. Cells were allowed to attach to culture dishes for 24 hours, then C1B5 
peptide (0.1 or 1M per well) was added to the wells. At various time points, the number 
of cells was counted using a hemocytometer. 
  Assay of anchorage-independent cell growth. The anchorage-independent growth of 
colon cancer cells was determined by culturing the cells in double layered soft agar. 
Either 2 x 104 or 5 x 104 cells in serum free Ham’s F-12 medium were mixed with 0.4 % 
agar (total volume of 0.5 ml) and placed on top of the bottom layer of 0.8% agar (0.5 ml). 
Both concentrations of agar were dissolved in serum free Ham’s F-12 medium. Various 
concentrations of the C1B peptides  in 100 µl Ham’s F-12 medium and/or 1 M 
Ro-32-0432 were placed on top of the soft agar one day after starting the culture. The 
cells were cultured for 7 days in 5% CO2 humidified air at 37°C. Colonies with diameters 
over 50 μm were counted by an automated colony counter (Olympus CKX41 inverted 
microscope equipped with computerized motor-driven stage, ALTRA20 CMOS camera 
and analysis software MicroSuite FiVE).  
  Cell cycle analysis. To analyze the effect of C1B5 on COLO 205 cells, cell cycle 
analysis was carried out using propidium iodide staining. In brief, 2.5x105 COLO205 
cells were seeded in 6-well plates and left overnight. The next day, cells were treated with 
1µM C1B5 and allowed to grow for 72 hours. At the end of the incubation, cells were 
collected by trypsinization and fixed overnight in 70% pre-chilled ethanol. After 
collection of the cells by centrifugation, cells were incubated in PBS containing 40 µg/ml 
propidium iodide and 100 µg/ml RNase A for 1 hour at room temperature. The 
fluorescence (excitation at 488 nm and emission at 585/42 nm) of 20,000 cells from each 
sample was measured with a FACS Calibur flow cytometer (Becton Dickinson, San Jose, 
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CA). Data were analyzed using ModFit software and the results were displayed as 
histograms.  
  Apoptosis detection by flow cytometry. COLO205 cells were seeded and cultured for 
72 hours in serum-free RPMI-1640 medium with or without 1μM C1B5 peptide. The 
proportion of apoptotic cells was analyzed using an Annexin V-FITC apoptosis detection 
kit (Biovision, Mountain View, CA) with fluorescence activated cell sorting (FACS) 
using FACS Vantage SE flow cytometer (BD Biosciences, San Jose, CA). 
  Western blot analysis. Total cellular protein was prepared using RIPA buffer 
supplemented with protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). 
Protein samples were separated by 10% acrylamide SDS-PAGE, electrotransferred onto 
nitrocellulose membrane (GE Healthcare), and blocked with 4% bovine serum albumin 
(BSA) in PBST (0.1% Tween20 in PBS) for 1 hour at room temperature. The membranes 
were washed and incubated with antibodies against phospho-PKCα/βII (1:500), cleaved 
caspase-3 (1:1000), p53 Ser15 (1:500) and Ser20 (1:500), total p53 (1:500), PKCα 
(1:1000) or PKCβII (1:1000) with 0.1% BSA in PBST for 1 hour at room temperature. 
Subsequent incubation with a horseradish peroxidase-conjugated anti-rabbit IgG 
antibody at a 1:2000 dilution with 0.1% BSA in PBST was done for another 1 hour at 
room temperature.  The protein expression signal was detected with SuperSignal West 
Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford, IL). GAPDH 
was used as the loading control of sample by re-probing with an anti-GAPDH antibody at 
a 1:4000 dilution. The levels of the p53 phosphorylated at serine 20 was normalized by 
corresponding total p53 levels. 
  Xenografted tumor growth in SCID mice and tumor tissue collection. COLO205 
human colon carcinoma cells were subcutaneously injected into 6-week-old female 
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C.B-17 SCID mice (Charles River Laboratories, Inc. Wilmington, MA). The cancer cells 
(1 x 107 cells) suspended in 100 µl 0.6% agar in RPMI1640 medium were injected to the 
both flanks of each mouse. The tumor size was measured using a caliper every 3 days; 
tumor volume was estimated by the formula (length) x (width) 2 x 1/2. After tumor 
volume reached 150 mm3, C1B5 or scrambled peptide (20 mg/kg body weight) was 
injected intratumorally every 3 days (n=5). Sterile PBS was injected into the control 
groups (n=5). The mice were sacrificed three days after the last treatment, and the tumors 
were collected and weighed. All tumor tissues were fixed in 10% buffered-formalin and 
paraffin embedded for histologic examination. Thin sections, 4 m thick, were stained 
with hematoxylin and eosin (H&E). The mean number of mitotic figures in a high power 
field (400x) was calculated. All experiments were carried out under the approval of the 
Kansas State University IACUC and IBC. 
  Immunohistochemical determination of cell proliferation and TUNEL assay. 
Immunohistochemical analysis of cell proliferation in tumor tissues was carried out by 
counting the numbers of Ki-67 positive cells in tumors. After deparaffinization of the thin 
sections, heat-induced epitope unmasking was performed in citrate buffer, followed by 
incubation with 3% H2O2/methanol for 5 min to block endogenous peroxidase activity. 
Sections were incubated with polyclonal anti-Ki-67 antibody at 1:100 dilution for 1 h at 
37oC. Then, sections were reacted with a biotin-conjugated anti-rabbit IgG antibody 
(Vector Laboratories) at 1:100 dilution for 1 h at 37oC, followed by reaction with 
avidin–biotin peroxidase complex reagent (Vector Laboratories). Reactions were 
developed with 3, 3-diaminobenzodine tetrahydrochloride (Sigma) and counterstained 
lightly with hematoxylin.  
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  To determine apoptosis in the tumors, the DeadEndTM colorimetric TUNEL system 
(Promega, Madison, WI) was used according to the manufacturer’s protocol with slight 
modifications. The tissue sections were counterstained with methyl green after TUNEL 
staining.  
  The cell proliferation or apoptotic index was determined by counting either Ki-67 
positive cells or TUNEL positive cells, respectively, in 10 randomly selected fields at 
400x magnification. The cell proliferation or apoptotic index was expressed as the mean 
number of positive cells/field. 
  Statistical analysis. The means of the experimental groups were evaluated to confirm 
that they met the normality assumption. All the in vitro data were represented as mean ± 
standard error (SE) on graphs. Statistical analysis was carried out by  ANOVA and student t test as 
a post-hoc analysis. To evaluate the significance of overall differences in tumor size 
between two groups, statistical analysis was performed by ANOVA, using Fisher’s 
protected least significance difference (PLSD) as a post hoc test. A p-value less than 0.05 
was considered significant. All the tumor size data were represented as mean ± standard 
error on graphs. Statistical analyses were performed by Stat View software, version 5.0.1. 
(JMP, Cary, NC). 
 
Acknowledgements 
The authors thank Marla Pyle (Department of Anatomy and Physiology, Kansas State 
University) for critical reading and constructive comments during the preparation of the 
manuscript. This work was supported in part by the Kansas State University (KSU) Terry 
C. Johnson Center for Basic Cancer Research, KSU Provost’s Fund, KSU College of 
Veterinary Medicine Dean’s Fund, NIH grants P20 RR017686 and p20 RR1556, and the 
 18
Kansas Bioscience Authority Collaborative Cancer Research grant. 
 
References 
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:2777-300. 
2. Fearon E. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 
   278:1043-50. 
3. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature  
   1984; 308:693-8. 
4. Kikkawa U, Kishimoto A, Nishizuka Y. The protein kinase C family: heterogeneity and its implications.  
    Annu Rev Biochem 1989; 58:31-44. 
5. Clemens MJ, Trayner I, Menaya J. The role of protein kinase C isoenzymes in the regulation of cell 
    proliferation and differentiation. J Cell Sci 1992; 103:881-7. 
6. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads  
    memorial award lecture. Cancer Res 1988; 48:1-8. 
7. Nguyen T, Takemoto, LJ, Takemoto DJ. Inhibition of gap junction activity through the release of the C1B 
   domain of protein kinase Cgamma (PKCgamma) from 14-3-3: identification of PKCgamma-binding 
   sites. J Biol Chem 2004; 279:52714-25. 
8. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer  
   2007; 7:281-94. 
9. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of  
   calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol  
   Chem 1982; 257:7847-51. 
10. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 2003;  
      10:389-96. 
11. Craven PA, DeRubertis FR. Loss of protein kinase C delta isozyme immunoreactivity in human 
       adenocarcinomas. Dig Dis Sci 1994; 39:481-9. 
12. Wali RK, Frawley BP, Jr., Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, et al. Mechanism of  
      action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis:  
      potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 1995; 55:5257-64. 
13. Cerda SR, Bissonnette M, Scaglione-Sewell B, Lyons MR, Khare S, Mustafi R, et al. PKC-delta inhibits 
     anchorage-dependent and -independent growth, enhances differentiation, and increases apoptosis in  
     CaCo-2 cells. Gastroenterology 2001; 120:1700-12. 
14. Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C betaII is  
      an early promotive event in colon carcinogenesis. Cancer Res 2001:1375-81. 
15. Murray NR, Davidson LA, Chapkin RS, Gustafson CW, Schattenberg DG AP. F. Overexpression of 
 19
      protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon  
      carcinogenesis. J Cell Biol 1999; 145:699-711. 
16. Murray NR, Weems C, Chen L, Leon J, Yu W, Davidson LA, et al. Protein kinase C betaII and  
      TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol 2002; 
      157:915-20. 
17. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors 
       of protein kinase C. Biochem J 1993; 292:335-7. 
18. Birchall AM, Bishop J, Bradshaw D, Cline A, Coffey J, Elliott LH, et al. Ro 32-0432, a selective and  
      orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Ther. 1994;  
      268:922-9. 
19. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase 
      Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT  
      pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma  
      xenografts. Cancer Res 2005; 65:7462-9. 
20. Mroz RM, Holownia A, Chyczewska E, Chyczewski L, Braszko JJ. p53 N-terminal Ser-15 
      approximately P and Ser-20 approximately P levels in squamous cell lung cancer after  
      radio/chemotherapy. Am J Respir Cell Mol Biol 2004; 30:564-8. 
21. Borner C, Ueffing M, Jaken S, Parker PJ, Weinstein IB. Two closely related isoforms of protein kinase 
      C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. J Biol  
      Chem 1995; 270:78-86. 
22. Choi PM, Tchou-Wong KM, Weinstein IB. Overexpression of protein kinase C in HT29 colon cancer 
       cells causes growth inhibition and tumor suppression. Mol Cell Biol 1990; 10:4650-7. 
23. Goldstein DR, Cacace AM, Weinstein IB. Overexpression of protein kinase C beta 1 in the SW480 
       colon cancer cell line causes growth suppression. Carcinogenesis 1995; 16:1121-6. 
24. Fields AP, Calcagno SR, Krishna M, Rak S, Leitges M, Murray NR. Protein kinase Cbeta is an effective 
       target for chemoprevention of colon cancer. Cancer Res 2009; 69:1643-50. 
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10. 
26. Leonard TA, Różycki B, Saidi LF, Hummer G, Hurley JH. Crystal structure and allosteric activation of 
      protein kinase C βII. Cell 2011; 144:55-66. 
27. Pysz MA, Leontieva OV, Bateman NW, Uronis JM, Curry KJ, Threadgill DW, et al. PKCalpha tumor  
      suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. 
      Exp Cell Res 2009; 315:1415-28. 
28. Saxon ML, Zhao X, Black JD. Activation of protein kinase C isozymes is associated with post-mitotic 
       events in intestinal epithelial cells in situ. J Cell Biol. 1994; 126:747-63. 
29. Verstovsek G, Byrd A, Frey MR, Petrelli NJ, Black JD. Colonocyte differentiation is associated with 
      increased expression and altered distribution of protein kinase C isozymes. Gastroenterology 1998;  
 20
       115:75-85. 
30. Frey MR, Clark JA, Leontieva O, Uronis JM, Black AR, Black JD. Protein kinase C signaling mediates 
      a program of cell cycle withdrawal in the intestinal epithelium. J Cell Biol 2000; 154:763-78. 
31. Oster H, Leitges M. Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in  
       ApcMin/+ mice. Cancer Res 2006; 66:6955-63. 
 
Figure legends 
Figure 1. C1B peptides significantly inhibit anchorage-independent growth of human 
colon cancer cells. Colonies over 50µm diameter were counted by an automated colony 
counter as described in the Materials and Methods. COLO205 cells (2 x 104) were 
cultured in soft agar in the presence or absence of various concentrations of C1B5 (A) or 
C1B1 peptide (B) for 7 days. (C) Colony size was also significantly smaller in the C1B 
peptide-treated group. Original magnification is x100. (D) C1B5 peptide (1 µM) 
effectively attenuated colony growth in two other human colon cancer cell lines, SW620 
and Caco-2. Data are expressed as mean ± S.E. Asterisks indicate significantly different 
values (P < 0.05) when compared with the control. 
 
Figure 2. C1B5 peptide did not affect the growth of RIE-1 normal intestinal epithelial 
cells or COLO 205 cells in 2D culture. Cells were cultured in the absence (white bars) or 
presence of 0.1 µM (gray bars) or 1 µM (black bars) C1B5 peptide for various time 
periods as indicated in the figure. Dead cells were stained with trypan blue and the cell 
numbers were analyzed using a hemocytometer. Data are expressed as mean ± S.E.  
 
Figure 3. Inhibition of anchorage independent growth by C1B5 peptide is reversed by 
PCK-specific inhibitor.  As in Figure 1, a soft agar assay was used and COLO205 
colonies were counted with an automated colony counter. Pretreatment with the PKC- 
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inhibitor, Ro-32-0432 (1 µM), counteracted C1B5-induced colony growth attenuation. 
These data are representative of two independent analyses with triplicate determinations. 
Data are expressed as mean ± S.E. An asterisk indicates significantly different value (P < 
0.05) when compared with the control. 
 
Figure 4. C1B5 peptide treatment significantly increased the G2 population (panels A and 
B), both early and late-stage apoptosis (panels C and D), and cleaved caspase 3 and 
phosphorylated p53 of COLO205 cells (panels E and F). COLO205 cells were incubated 
for 72 hours with 1 µM C1B5 peptide. Cells were dispersed by trypsinization and 
incubated with either propidium iodide for cell cycle analysis or annexin V-FITC for 
apoptosis analysis by flow cytometry as described in Materials and Methods. These 
data are representative of two independent analyses with triplicate determinations. Both 
early apoptosis (as shown in lower right quadrant) and late apoptosis (upper right 
quadrant) increased significantly with the addition of C1B5 (panel D). Samples for the 
Western blot analysis were collected either at 48 or 72 hours. Sample preparation and 
Western blot analysis were performed three times with duplicate determinations. The 
pictures in panel E represent typical blotting results. An asterisk indicates a significantly 
different value (P < 0.05) when compared with the control.  
   
Figure 5. The effect of C1B5 treatment on the expression of various PKC isozymes, PKC 
phosphorylation, cleaved caspase-3, total p53, and phosphorylated p53 in COLO205 was 
analyzed by Western blot analysis. C1B5 significantly decreased levels of 
phosphorylated PKCII after 30 minutes of exposure (Panels A and D). In contrast, the 
levels of non-phosphorylated PKCα and were increased by the C1B5 treatment (Panels 
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A, B and C). The level of cleaved caspase-3 was significantly increased at 6 hours (Panels 
A and E). The expression levels of total p53 and phosphorylated p53 at serine 20 were 
significantly increased after C1B5 treatment (Panels A, F, and G). Samples were prepared 
and subjected to Western blot analysis as described in Materials and Methods. Sample 
preparation and Western blot analysis were performed three times with duplicate 
determinations. The pictures in Panel A represent typical blotting results. Asterisks 
indicate significantly different values (P < 0.05) when compared with the 0 h time point. 
 
Figure 6. Intratumoral injection of C1B5 peptide significantly attenuated the growth of 
COLO205 subcutaneous xenografts in SCID mice (n= 5, panels A and B).  Histologically, 
the number of mitotic figures was significantly smaller in the C1B5 treated group tumors 
than in the scrambled peptide and PBS control group tumors (panels C and D).  The H&E 
sections show the mitotic figures (arrows, panel C, 400x magnification).  In this 
experiment, COLO205 cells were inoculated subcutaneously to both flanks of SCID mice 
at 1x107 cells per site.  When tumors reached an average volume of 150 mm3, C1B5, 
scrambled peptide or PBS was injected into the tumors. The treatment was initiated at day 
22 after tumor cell inoculation and repeated every 3 days for 15 days. Mice were 
sacrificed 3 days after the final treatment.  The number of mitotic figures in 10 randomly 
selected fields at high power field (400x) was counted and the mean number of mitotic 
figures was expressed. Data are expressed as mean ± S.E. Asterisks indicate significantly 
different values (P < 0.05) when compared with the PBS control. 
 
Figure 7. Immunohistochemical analysis of cell proliferation (panels A, B, and E) and 
apoptosis (panels C, D, and F) in COLO205 subcutaneous xenografts in SCID mice 
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treated intratumorally with either PBS (panels A and C) or C1B5 (panels B and D). 
Xenografts were collected as described in the Methods section. Cell proliferation in 
COLO205 xenografts was analyzed by counting the number of Ki-67 positive cells 
(panels A and B). Apoptosis was analyzed by counting TUNEL positive cells in the 
tumors (panels C and D). The average numbers of Ki-67 positive cells (E) and TUNEL 
positive cells (F) per high power field (400x) were determined by analyzing ten fields in 
each treatment group and are expressed in the bar graph. The original magnification of 
panels A-D was 400x. Asterisks indicate significantly different values (P < 0.05) when 
compared with the PBS control. 
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